Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex

You may also be interested in...

Green Cross Concludes Takeover Deal Of Innocell; Looks To Overseas Markets For Growth

Korea’s Green Cross to continue development of Innocell’s Immuncell-LC cancer cell therapy after becoming the major shareholder of the troubled company.

Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms

TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing

Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds

SEOUL - Green Cross Corp. has continued a trend among Korean pharma companies by posting relatively sluggish second quarter results

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts